- Deal value of up to US$525 million
- Novo Holdings co-led ReViral Series B financing in 2018
- ReViral developing novel antiviral therapies to treat RSV infections
- Validation of Novo Holdings’ strategy to identify and invest in high quality European biotech opportunities
Copenhagen, Denmark – Novo Holdings A/S, a leading international life sciences investor, today announces that its portfolio company ReViral Ltd (ReViral), has entered into a definitive agreement to be acquired by Pfizer (NYSE: PFE) for up to US$525 million in total deal value.